US regulators expand use of Allergan’s antibiotic
The US Food and Drug Administration has agreed to expand the label of Dublin, Ireland-based Allergan’s Avycaz to include the treatment of complicated urinary tract infections (cUTI).
Read More
Tag: Avycaz
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
